Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to Piccaluga et al

Leukemia volume 19, page 136 (2005)Cite this article

TO THE EDITOR

We read with interest the comments by Dr Piccaluga et al1, 2 regarding our report on the use of alemtuzumab in an adult patient with refractory acute lymphocytic leukemia (ALL), who has now remained in complete remission for 20 months and remains so at the time of writing, albeit still without complete recovery of normal blood counts, as initially reported.3

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Visani G, Baccarani M . Alemtuzumab in the treatment of relapsed acute lymphoid leukemia. Leukemia 2005; 19: 135.

    Article  CAS  Google Scholar 

  2. Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bianchini M, Vigna E et al. Anti leukemic and anti GVHD effects of Campath 1H in acute lymphoblastic leukemia relapsed after stem cell transplantation. Leukemia Lymphoma 2004; 45: 731–733.

    Article  CAS  Google Scholar 

  3. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin NC . Remission of adult acute lymphocytic leukemia with alemtuzumab. Leukemia 2004; 18: 1557–1558.

    Article  CAS  Google Scholar 

  4. Avivi I, Chakrabarti S, Kottaridis P, Kyriaku C, Dogan A, Milligan DW et al. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 2004; 34: 137–142.

    Article  CAS  Google Scholar 

  5. Gorin NC, Labopin M, Polge E, Cordonnier C, Jouet JP, Michallet M et al. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia 2003; 17: 1596–1599.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Cell Therapy, Centre Hospitalo Universitaire Saint-Antoine and Université Paris 6, 184 Rue Du Faubourg Saint-Antoine, Paris, France

    J-P Laporte, F Isnard, L Fouillard, L Garderet & N-C Gorin

Authors
  1. J-P Laporte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Isnard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Fouillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Garderet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N-C Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laporte, JP., Isnard, F., Fouillard, L. et al. Reply to Piccaluga et al. Leukemia 19, 136 (2005). https://doi.org/10.1038/sj.leu.2403579

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403579

Search

Advanced search

Quick links